Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.

about

Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors.Asymmetric Formal Synthesis of the Long-Acting DPP-4 Inhibitor Omarigliptin.

P2860

Q38417418-F6103776-09C1-4AAD-8F53-6169EA076A17 Q48292533-97DAFA46-28C9-4CB3-90C7-9D70CBF3E323

P2860

Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.

Item

http://www.wikidata.org/entity/Q38244605

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.

@en

type

Item

label

Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.

@en

prefLabel

Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.

@en

P1476

Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.

@en

P2093

Ernest Adeghate

http://www.w3.org/2001/XMLSchema#string

Erzsébet Fehér

http://www.w3.org/2001/XMLSchema#string

Huba Kalász

http://www.w3.org/2001/XMLSchema#string

P2860

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

Alpha lipoic Acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials

Randomized control trial of topical clonidine for treatment of painful diabetic neuropathy

Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitati

Topiramate in the new generation of drugs: efficacy in the treatment of alcoholic patients.

NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential

Effects of treatments for symptoms of painful diabetic neuropathy: systematic review

Diabetic neuropathies: diagnosis and management

alpha-Lipoic acid as a biological antioxidant.

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

P304

1-15

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.2014.954033

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2014-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25171371

http://www.w3.org/2001/XMLSchema#string

Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.

about

P2860

P2860

Evaluating the Phase II drugs currently under investigation for diabetic neuropathy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698